# KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial

> **NCT04844619** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 40 (estimated)

## Conditions studied

- Neovascular Glaucoma
- Neovascularization

## Interventions

- **DRUG:** 4mg/ml KDR2-2 suspension eyedrop
- **DRUG:** 16mg/ml KDR2-2 suspension eyedrop

## Key facts

- **NCT ID:** NCT04844619
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-19
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04844619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04844619, "KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04844619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*